Modus Advisors LLC Grows Stock Position in Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Modus Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 10,168 shares of the company’s stock after buying an additional 373 shares during the period. Modus Advisors LLC’s holdings in Johnson & Johnson were worth $1,671,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in JNJ. Cypress Point Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $25,000. Iron Horse Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $30,000. Joseph P. Lucia & Associates LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $32,000. Klaas Financial Asset Advisors LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $36,000. Finally, Interactive Financial Advisors purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $39,000. Hedge funds and other institutional investors own 67.25% of the company’s stock.

Several equities research analysts recently issued reports on the company. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $175.00 to $190.00 and gave the stock an “overweight” rating in a report on Wednesday, January 27th. SVB Leerink lifted their price objective on Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. Cowen lifted their price objective on Johnson & Johnson from $170.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $157.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, January 27th. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $178.60.

Shares of JNJ stock traded up $0.24 during trading on Thursday, hitting $163.85. 44,240 shares of the stock traded hands, compared to its average volume of 8,177,090. The firm has a market capitalization of $431.37 billion, a P/E ratio of 25.76, a price-to-earnings-growth ratio of 3.06 and a beta of 0.70. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The firm’s fifty day moving average price is $161.06 and its 200-day moving average price is $154.38. Johnson & Johnson has a 52-week low of $133.65 and a 52-week high of $173.65.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Monday, January 25th. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.82 by $0.04. The company had revenue of $22.50 million for the quarter, compared to analyst estimates of $21.62 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.88 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current year.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: Quiet Period

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.